OncoSil Medical Limited (ASX:OSL)
Australia · Delayed Price · Currency is AUD 0.9700
-0.0050 (-0.51%)
Sep 17, 2026, 4:10 PM AEST
OncoSil Medical Earnings Call Transcripts
Fiscal Year 2026
-
FDA granted HDE approval for OncoSil, the first Class III device for unresectable, non-metastatic distal cholangiocarcinoma, enabling U.S. marketing with initial use limited to five centers and 30 patients. Broader rollout and revenue depend on completing a post-approval study, with full launch targeted for the second half of FY 2027.